Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (492) 492
Publication (110) 110
Book Chapter (6) 6
Conference Proceeding (4) 4
Patent (3) 3
Book Review (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (217) 217
humans (214) 214
male (129) 129
female (124) 124
middle aged (105) 105
aged (102) 102
pathology (92) 92
article (87) 87
adult (76) 76
cancer (72) 72
oncology (71) 71
tumors (71) 71
surgery (67) 67
aged, 80 and over (63) 63
gastroenterology and hepatology (59) 59
diagnosis (58) 58
animals (52) 52
gastroenterology & hepatology (52) 52
mutation (52) 52
immunohistochemistry (51) 51
abridged index medicus (48) 48
adenocarcinoma (45) 45
pancreatic neoplasms - pathology (44) 44
pancreas (43) 43
prognosis (38) 38
carcinoma (37) 37
lung cancer (37) 37
lung neoplasms - genetics (36) 36
medicine, research & experimental (36) 36
adenocarcinoma - pathology (35) 35
management (35) 35
biopsy (34) 34
respiratory system (34) 34
lung neoplasms - pathology (33) 33
carcinoma, pancreatic ductal - pathology (31) 31
mice (31) 31
research (29) 29
pancreatic cancer (28) 28
retrospective studies (28) 28
care and treatment (27) 27
diagnosis, differential (27) 27
survival (26) 26
classification (25) 25
expression (25) 25
adenocarcinoma, mucinous - pathology (24) 24
medical laboratory technology (23) 23
dysplasia (22) 22
lung neoplasms - drug therapy (21) 21
neoplasm staging (21) 21
cell biology (20) 20
cell line, tumor (20) 20
neoplasms (20) 20
resection (20) 20
carcinoma, non-small-cell lung - genetics (19) 19
chemotherapy (19) 19
mutations (19) 19
young adult (19) 19
adenocarcinoma - genetics (18) 18
pancreas - pathology (18) 18
risk factors (18) 18
sensitivity and specificity (18) 18
swine (18) 18
treatment outcome (18) 18
metastasis (17) 17
pancreatic neoplasms - surgery (17) 17
adolescent (16) 16
features (16) 16
follow-up studies (16) 16
health aspects (16) 16
intraductal papillary mucinous neoplasm (16) 16
carcinoma, pancreatic ductal - surgery (15) 15
crizotinib (15) 15
cytology (15) 15
disease models, animal (15) 15
international consensus guidelines (15) 15
ipmn (15) 15
lung neoplasms - metabolism (15) 15
medical colleges (15) 15
tomography, x-ray computed (15) 15
carcinoma, non-small-cell lung - drug therapy (14) 14
carcinoma, papillary - pathology (14) 14
cells (14) 14
egfr (14) 14
gefitinib (14) 14
gene (14) 14
in situ hybridization, fluorescence (14) 14
lung neoplasms - diagnosis (14) 14
methods (14) 14
patients (14) 14
reproducibility of results (14) 14
usage (14) 14
analysis (13) 13
biomarkers (13) 13
biomarkers, tumor - genetics (13) 13
cysts (13) 13
lung - pathology (13) 13
malignancy (13) 13
multidisciplinary sciences (13) 13
pancreatic neoplasms - diagnosis (13) 13
protein kinase inhibitors - pharmacology (13) 13
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Dr. Mari Mino-Kenudson: challenges and future developments in the field of biopsy
by Li, G and Liu, M and Mino-Kenudson
TRANSLATIONAL LUNG CANCER RESEARCH, ISSN 2218-6751, 12/2017, Volume 6, Issue Suppl 1, pp. S97 - S98
ONCOLOGY | RESPIRATORY SYSTEM | Meet the Professor
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Immunohistochemistry in anaplastic lymphoma kinase and proto-oncogene tyrosine-protein kinase ROS
by Mino-Kenudson, Mari
Archives of Pathology and Laboratory Medicine, ISSN 0003-9985, 07/2018, Volume 142, Issue 7, pp. 792 - 793
Of those, IHC is widely available in pathology laboratories worldwide, is less challenging technically, can provide clinically meaningful results with a rapid... 
MEDICINE, RESEARCH & EXPERIMENTAL | LUNG-CANCER PATIENTS | MOLECULAR TESTING GUIDELINE | INHIBITORS | MEDICAL LABORATORY TECHNOLOGY | PATHOLOGY | SELECTION | ALK REARRANGEMENT | Immunohistochemistry | Adenocarcinoma | Evaluation | Reactive oxygen species | Molecular diagnostic techniques | Innovations | Practice guidelines (Medicine) | Genetic aspects | Diagnosis | Gene expression | Health aspects | Methods | Tyrosine | Laboratories | Lung cancer | Cloning | Kinases | Lymphoma | Studies | Proteins | Pathology | Protein kinase | Biomarkers | Lymphomas | Protein-tyrosine kinase | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
by Mino-Kenudson, Mari
Cancer Biology and Medicine, ISSN 2095-3941, 06/2016, Volume 13, Issue 2, pp. 157 - 170
Blockade of immune checkpoints has recently emerged as a novel therapeutic strategy in various tumors. In particular, monoclonal antibodies targeting... 
Immunohistochemistry | PD-L1 | Biomarker | PD-1 | Predictive | MEDICINE, RESEARCH & EXPERIMENTAL | ACTIVATION | ONCOLOGY | B7-H1 EXPRESSION | POOR-PROGNOSIS | IMMUNE ESCAPE | ANTIBODY | PULMONARY ADENOCARCINOMA | BLOCKADE | CLINICOPATHOLOGICAL ANALYSIS | UP-REGULATION | ASSOCIATION | predictive | Review | immunohistochemistry | biomarker
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Programmed death-ligand 1 immunohistochemistry testing for non-small cell lung cancer in practice
: PD-L1 Immunohistochemistry in NSCLC
by Mino-Kenudson, Mari
Cancer Cytopathology, ISSN 1934-662X, 07/2017, Volume 125, Issue 7, pp. 521 - 528
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Cytological reporting on lung FNA and small biopsy specimens in the era of personalized medicine
: Cytological Reporting
by Mino-Kenudson, Mari
Cancer Cytopathology, ISSN 1934-662X, 03/2017, Volume 125, Issue 3, pp. 155 - 160
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Programmed death‐ligand 1 immunohistochemistry testing for non‐small cell lung cancer in practice
by Mino‐Kenudson, Mari
Cancer Cytopathology, ISSN 1934-662X, 07/2017, Volume 125, Issue 7, pp. 521 - 528
Given the recent approval by the US Food and Drug Administration of an anti‐programmed cell death protein 1 agent as a first‐line therapy for patients with... 
SQUAMOUS-CELL | PEMBROLIZUMAB | NSCLC | ONCOLOGY | PD-L1 EXPRESSION | ADENOCARCINOMAS | ASSAYS | PATHOLOGY | NIVOLUMAB | DOCETAXEL | ASSOCIATION | DIAGNOSTIC IMMUNOHISTOCHEMISTRY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Area of residual tumor is a robust prognostic marker for patients with rectal cancer undergoing preoperative therapy
by Sakuyama, Naoki and Kojima, Motohiro and Kawano, Shingo and Matsuda, Yoko and Mino‐Kenudson, Mari and Ochiai, Atsushi and Ito, Masaaki
Cancer Science, ISSN 1347-9032, 03/2018, Volume 109, Issue 3, pp. 871 - 878
The aim of this study was to elucidate differences in the histological features of rectal cancer between patients treated with preoperative chemoradiotherapy... 
neoadjuvant chemotherapy | preoperative chemoradiotherapy | area of residual tumor | pathological assessment | rectal cancer | SURVIVAL | CELLS | RESECTION | POSTOPERATIVE CHEMORADIOTHERAPY | ONCOLOGY | CHEMORADIATION | RADIOTHERAPY | EXCISION | CARCINOMA | ASSOCIATION | EXPRESSION | Medical research | Cancer patients | Care and treatment | Chemotherapy | Prognosis | Colorectal cancer | Medicine, Experimental | Health aspects | Tumors | Cancer | Acetylcysteine | Sphincter | Cancer therapies | Patients | Medical prognosis | Surgery | Rectum | Fibrosis | Conflicts of interest | Hypoxia | Methods | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Tumor islands and spread through air spaces: Distinct patterns of invasion in lung adenocarcinoma
by Morales‐Oyarvide, Vicente and Mino‐Kenudson, Mari
Pathology International, ISSN 1320-5463, 01/2016, Volume 66, Issue 1, pp. 1 - 7
Lung adenocarcinoma is a highly heterogeneous disease and the heterogeneity is associated with various patient outcomes even in early‐stage tumors. In order to... 
air space invasion | spread through air spaces | lung adenocarcinoma | micropapillay | tumor islands | Air space invasion | Lung adenocarcinoma | Tumor islands | Micropapillay | Spread through air spaces | MICROPAPILLARY PATTERN | IASLC/ATS/ERS CLASSIFICATION | LIMITED RESECTION | PATHOLOGY | EGFR | POOR-PROGNOSIS | HISTOLOGIC SUBTYPE | INTERNATIONAL ASSOCIATION | RECURRENCE | PROGNOSTIC-SIGNIFICANCE | CARCINOMA | Lung Neoplasms - classification | Adenocarcinoma - pathology | Adenocarcinoma of Lung | Neoplasm Invasiveness | Adenocarcinoma - classification | Humans | Lung Neoplasms - pathology | Neoplasm Staging | Adenocarcinoma | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
by Pfirschke, Christina and Engblom, Camilla and Rickelt, Steffen and Cortez-Retamozo, Virna and Garris, Christopher and Pucci, Ferdinando and Yamazaki, Takahiro and Poirier-Colame, Vichnou and Newton, Andita and Redouane, Younes and Lin, Yi-Jang and Wojtkiewicz, Gregory and Iwamoto, Yoshiko and Mino-Kenudson, Mari and Huynh, Tiffany G and Hynes, Richard O and Freeman, Gordon J and Kroemer, Guido and Zitvogel, Laurence and Weissleder, Ralph and Pittet, Mikael J
Immunity, ISSN 1074-7613, 02/2016, Volume 44, Issue 2, pp. 343 - 354
Checkpoint blockade immunotherapies can be extraordinarily effective, but might benefit only the minority of patients whose tumors are pre-infiltrated by... 
LUNG-CANCER | RESPONSES | MELANOMA | IMMUNOTHERAPY | PD-1 BLOCKADE | ANTICANCER THERAPIES | MOUSE MODEL | ANTITUMOR IMMUNITY | IMMUNOLOGY | CANCER-THERAPY | T-CELLS | Cyclophosphamide - administration & dosage | Immunotherapy - methods | Adenocarcinoma - immunology | Humans | Mice, Inbred C57BL | Genes, cdc - drug effects | Lung Neoplasms - therapy | Lymphocytes, Tumor-Infiltrating - drug effects | Immunity, Innate | Toll-Like Receptor 4 - metabolism | Mice, Knockout | Lung Neoplasms - immunology | Organoplatinum Compounds - administration & dosage | Animals | Adenocarcinoma - therapy | Drug Therapy - methods | CD8-Positive T-Lymphocytes - drug effects | Cell Line, Tumor | Mice | Mice, Inbred BALB C | Central Nervous System Sensitization - drug effects | Disease Models, Animal | Prevention | Cyclophosphamide | Chemotherapy | Immune response | Analysis | Oncology, Experimental | Immunotherapy | Research institutes | Research | T cells | Cancer | Drugs | Flow cytometry | Cloning | Mortality | Cytotoxicity | Experiments | Cancer therapies | Manuscripts | Lungs | Lymphocytes | Rodents | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes
by Rosenbaum, Matthew W and Bledsoe, Jacob R and Morales-Oyarvide, Vicente and Huynh, Tiffany G and Mino-Kenudson, Mari
Modern Pathology, ISSN 0893-3952, 09/2016, Volume 29, Issue 9, pp. 1104 - 1112
Programmed cell death 1 (PD-1) and its ligand (PD-L1) are key suppressors of the cytotoxic immune response. PD-L1 expression on tumor cells may be induced by... 
PROGRAMMED CELL DEATH-1 | SAFETY | ANTIBODY | PATHOLOGY | BLOCKADE | CLINICOPATHOLOGICAL ANALYSIS | LIGAND 1 | Immunohistochemistry | Multivariate Analysis | Microsatellite Instability | Tumor Escape | Colorectal Neoplasms - genetics | Humans | Middle Aged | Tumor Microenvironment | Male | T-Lymphocytes, Cytotoxic - pathology | Young Adult | DNA Mutational Analysis | Aged, 80 and over | Adult | Female | Odds Ratio | Colorectal Neoplasms - mortality | T-Lymphocytes, Cytotoxic - immunology | Biomarkers, Tumor - analysis | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Logistic Models | Tumor Burden | Chi-Square Distribution | Colorectal Neoplasms - immunology | Lymphocytes, Tumor-Infiltrating - pathology | Proto-Oncogene Proteins B-raf - genetics | Aged | B7-H1 Antigen - analysis | Biomarkers, Tumor - genetics | Mutation | Colorectal Neoplasms - pathology | Neoplasm Staging | Lymphocytes, Tumor-Infiltrating - immunology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Crizotinib and testing for ALK
by Shaw, Alice T and Solomon, Benjamin and Mino-Kenudson, Mari
JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 12/2011, Volume 9, Issue 12, pp. 1335 - 1341
Crizotinib was recently approved by the US FDA for the treatment of advanced non-small cell lung cancer (NSCLC) harboring the ALK (anaplastic lymphoma kinase)... 
ALK | Crizotinib | Targeted therapy | Lung cancer | lung cancer | CELL LUNG-CANCER | targeted therapy | crizotinib | ONCOLOGY | ADENOCARCINOMA | EML4-ALK FUSION GENE | IN-SITU-HYBRIDIZATION | INHIBITOR | IDENTIFICATION | FEATURES | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Molecular Diagnostic Techniques - methods | Pyrazoles - therapeutic use | Prognosis | Pyridines - administration & dosage | Biomarkers, Tumor - analysis | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Carcinoma, Non-Small-Cell Lung - diagnosis | Molecular Targeted Therapy | Genetic Testing - methods | Pyrazoles - administration & dosage | Receptor Protein-Tyrosine Kinases - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Receptor Protein-Tyrosine Kinases - analysis | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Lung Neoplasms - diagnosis | Pyridines - therapeutic use
Journal Article
Details down arrow
12. Full Text Crizotinib for the Treatment of ALK‐Rearranged Non‐Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology
by Ou, Sai‐Hong Ignatius and Bartlett, Cynthia Huang and Mino‐Kenudson, Mari and Cui, Jean and Iafrate, A. John
The Oncologist, ISSN 1083-7159, 11/2012, Volume 17, Issue 11, pp. 1351 - 1375
Crizotinib, an ALK/MET/ROS1 inhibitor, was approved by the U.S. Food and Drug Administration for the treatment of anaplastic lymphoma kinase ( ALK )‐rearranged... 
Crizotinib | ROS1 inhibitor | Chromosomal rearrangements | ALK inhibitor | Receptor tyrosine kinase fusion positive malignancies | Non‐small cell lung cancer (NSCLC) | MET inhibitor | Non-small cell lung cancer (NSCLC) | EML4-ALK FUSION GENE | C-MET RECEPTOR | IN-SITU-HYBRIDIZATION | EGFR MUTATION | OPEN-LABEL | ANAPLASTIC LYMPHOMA KINASE | ONCOLOGY | NEVER-SMOKERS | GROWTH-FACTOR | RECEPTOR TYROSINE KINASE | ACTIVATING MUTATIONS | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Humans | Middle Aged | Male | Carcinoma, Non-Small-Cell Lung - diagnosis | Molecular Targeted Therapy | Genetic Variation | Young Adult | Pyridines - adverse effects | Drug Interactions | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Lung Neoplasms - genetics | Proto-Oncogene Proteins - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - genetics | Proto-Oncogene Proteins c-met - antagonists & inhibitors | In Situ Hybridization, Fluorescence | Signal Transduction - genetics | Pyrazoles - metabolism | Pyridines - metabolism | Receptor Protein-Tyrosine Kinases - genetics | Gene Rearrangement | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Lung Neoplasms - diagnosis | Protein-Tyrosine Kinases - antagonists & inhibitors | Academia-Pharma Intersect
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
by Kristin Bergethon and Alice T. Shaw and Sai-Hong Ignatius Ou and Ryohei Katayama and Christine M. Lovly and Nerina T. McDonald and Pierre P. Massion and Christina Siwak-Tapp and Adriana Gonzalez and Rong Fang and Eugene J. Mark and Julie M. Batten and Haiquan Chen and Keith D. Wilner and Eunice L. Kwak and Jeffrey W. Clark and David P. Carbone and Hongbin Ji and Jeffrey A. Engelman and Mari Mino-Kenudson and William Pao and A. John Iafrate
Journal of Clinical Oncology, ISSN 0732-183X, 03/2012, Volume 30, Issue 8, pp. 863 - 870
Purpose Chromosomal rearrangements involving the ROS1 receptor tyrosine kinase gene have recently been described in a subset of non-small-cell lung cancers... 
ANAPLASTIC LYMPHOMA KINASE | EML4-ALK | GLIOBLASTOMA | GEFITINIB | FUSION | GENE | ONCOLOGY | MUTATIONS | INHIBITORS | TUMORS | FEATURES | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Protein-Tyrosine Kinases - genetics | Aged, 80 and over | Adult | Female | Adenocarcinoma - genetics | Retrospective Studies | Pyrazoles - pharmacology | Pyridines - therapeutic use | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | In Situ Hybridization, Fluorescence | Proto-Oncogene Proteins - genetics | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Receptor Protein-Tyrosine Kinases - genetics | Protein Kinase Inhibitors - therapeutic use | Gene Rearrangement | Aged | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Drug Screening Assays, Antitumor | Original Reports | Thor9 | Thor2 | Thor12
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
by Alice T. Shaw and Beow Y. Yeap and Mari Mino-Kenudson and Subba R. Digumarthy and Daniel B. Costa and Rebecca S. Heist and Benjamin Solomon and Hannah Stubbs and Sonal Admane and Ultan McDermott and Jeffrey Settleman and Susumu Kobayashi and Eugene J. Mark and Scott J. Rodig and Lucian R. Chirieac and Eunice L. Kwak and Thomas J. Lynch and A. John Iafrate
Journal of Clinical Oncology, ISSN 0732-183X, 09/2009, Volume 27, Issue 26, pp. 4247 - 4253
Purpose The EML4-ALK fusion oncogene represents a novel molecular target in a small subset of non-small-cell lung cancers (NSCLC). To aid in identification and... 
ANAPLASTIC LYMPHOMA KINASE | GEFITINIB | GROWTH-FACTOR-RECEPTOR | ONCOLOGY | PHASE-II | FUSION GENE | EGFR MUTATIONS | KRAS | TUMORS | CHEMOTHERAPY | ERLOTINIB | Erlotinib Hydrochloride | Immunohistochemistry | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Oncogene Proteins, Fusion - metabolism | Age Factors | Protein-Tyrosine Kinases - metabolism | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Protein-Tyrosine Kinases - genetics | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Genes, ras - genetics | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Genotype | In Situ Hybridization, Fluorescence | Treatment Outcome | Receptor Protein-Tyrosine Kinases | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Oncogene Proteins, Fusion - genetics | Sex Factors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Original Reports | Thoracic Oncology | Thor12 | To8 | To20
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Cytological reporting on lung FNA and small biopsy specimens in the era of personalized medicine
by Mino‐Kenudson, Mari
Cancer Cytopathology, ISSN 1934-662X, 03/2017, Volume 125, Issue 3, pp. 155 - 160
Because of the advancement of personalized medicine in lung cancer, the subtyping of non–small cell lung cancer and predictive biomarker testing with... 
CANCER PATIENTS | ONCOLOGY | ADENOCARCINOMA | GUIDELINES | CLASSIFICATION | DIFFERENTIATION | PATHOLOGY | DOCETAXEL | EXPRESSION | CELL CARCINOMA | EGFR | IMMUNOHISTOCHEMISTRY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
by Mino-Kenudson, Mari
Cancer biology & medicine, ISSN 2095-3941, 06/2016, Volume 13, Issue 2, p. 157
Blockade of immune checkpoints has recently emerged as a novel therapeutic strategy in various tumors. In particular, monoclonal antibodies targeting... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Standardized terminology and nomenclature for pancreatobiliary cytology: The Papanicolaou Society of Cytopathology guidelines
by Pitman, Martha B and Centeno, Barbara A and Ali, Syed Z and Genevay, Muriel and Stelow, Ed and Mino‐Kenudson, Mari and Fernandez‐del Castillo, Carlos and Max Schmidt, C and Brugge, William and Layfield, Lester and Michael, Claire W and Papanicolaou Society of Cytopathology
Diagnostic Cytopathology, ISSN 8755-1039, 04/2014, Volume 42, Issue 4, pp. 338 - 350
The Papanicolaou Society of Cytopathology has developed a set of guidelines for pancreatobiliary cytology including indications for endoscopic ultrasound... 
PSC | nomenclature | guidelines | terminology | pancreas | DIFFERENTIAL-DIAGNOSIS | ACINAR-CELL CARCINOMA | NEUROENDOCRINE TUMORS | CYST FLUID ANALYSIS | PATHOLOGY |